Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors

NCT04767906 is registered in ClinicalTrials.gov with University of Leipzig as lead sponsor.

NCT NCT04767906
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04767906 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors
Lead sponsor
University of Leipzig
Phase
Phase 2
Overall status
Completed
Start date
December 14, 2021
Completion date
July 19, 2024
Enrollment
16 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma